查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423570

2030年全球乳癌藥物市場預測：依癌症類型、通路、最終用戶和地區進行分析

Breast Cancer Therapeutics Market Forecasts to 2030 - Global Analysis By Type (Hormonal Therapy, Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies), Cancer Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球乳癌藥物市場規模為 291 億美元，預計預測期內複合年成長率為 9.3%，到 2030 年將達到 543 億美元。

乳癌藥物是指各種旨在控制、治療和治癒乳癌的治療和介入措施。這些治療方法包括多種方法，包括手術、化療、放射線治療、標靶治療、荷爾蒙治療、免疫治療以及精準醫學和基因治療等新型治療方法。治療方法通常會根據癌症的階段、其獨特特徵以及患者個體的健康狀況和偏好而有所不同。

根據乳癌組織的統計數據，截至 2022 年 1 月，乳癌影響了超過 380 萬名美國女性。根據此統計，預計到2022年，女性新診斷癌症中約30%將是乳癌。

乳癌發生率上升

全球乳癌發生率不斷上升，推動了對治療方案的更大需求，並刺激了研究和開發。新技術提供更有針對性的治療方法，提高療效並減少副作用。人們對早期檢測的認知不斷提高，強調了對綜合治療解決方案的需求，並為市場擴張創造了環境。需求的激增推動了競爭激烈的市場競爭策略，促進了加強患者照護的合作，並推動了市場向前發展。

治療藥物的副作用

乳癌治療（例如標靶治療）產生的副作用可能會限制市場成長。對於嚴重的副作用，患者可能不再能夠使用該特定藥物，並且可能必須轉向其他類型的治療。治療的副作用可能很嚴重並影響患者的生活品質。

老年人口的擴大

世界人口老化正在增加癌症（包括乳癌）的發生率，對治療方案的需求也在增加。年齡較大是乳癌的主要危險因素，因此不斷成長的老年人口正在擴大潛在的患者群體。此外，該群體意識的提高和篩檢方法的改進為早期發現和早期療育提供了機會，從而促進更好的治療結果和市場擴張。

昂貴的治療費用

許多晚期乳癌治療費用昂貴，限制了保險不足或無力負擔的患者的治療機會。經濟挑戰導致創新藥物獲取機會不平等，影響治療效果和病患治療結果。高成本也會為醫療保健系統帶來負擔，限制資源，並限制新的、更容易取得的治療方法的研發。這些成本障礙阻礙了市場的成長。

COVID-19 的影響：

冠狀病毒的爆發擾亂了全球經濟，造成經濟負擔和經濟逆境。許多行業，包括醫療保健行業，都見證了巨大的轉變。優先考慮感染 COVID-19 的患者住院，並推遲其他醫療程序。疫情對全球市場的影響有限。

預計預測期內標靶治療領域規模最大

預計標靶治療細分市場將成為預測期內最大的細分市場。乳癌的標靶治療透過攻擊對癌症生長重要的特定分子，同時不傷害健康細胞，提供精確的治療。與傳統治療方法相比，它透過減少副作用和提高療效來改善患者的治療結果。它透過找出不同途徑來預防癌症進展的能力有望增強治療效果、提高存活率並改善患者的生活品質。

預計醫院藥房行業在預測期內的複合年成長率最高。

預計醫院藥房領域在預測期內的複合年成長率最高。醫院藥局透過確保及時獲得專門藥物、最佳化藥物治療方案和提供個人化護理，在乳癌治療中發揮著至關重要的作用。醫院藥局透過促進醫療團隊之間的無縫協作並確保準確的藥物管理和治療監控來改善患者的治療效果。

比最大的地區

由於政府的舉措和主要製藥公司的存在，預計北美在預測期內將佔據最大的市場佔有率。該地區充滿活力，不斷進行研究、臨床試驗以及製藥公司和研究機構之間的合作，推動創新。該地區還擁有強大的醫療基礎設施和優惠的報銷政策的支持，為患者提供先進的治療。

複合年成長率最高的地區：

由於意識提高、技術進步和醫療設施普及等多種因素，預計亞太地區在預測期內將維持最高的複合年成長率。個人化醫療的趨勢也在不斷成長，它根據腫瘤的特異性特徵調整趨勢。採用先進的診斷工具和治療方法顯著改善了患者的治療效果。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球乳癌治療市場：依治療方法

  • 荷爾蒙治療
    • Aromatase酶抑制劑
    • 雌激素受體下穩壓器(ERD)
    • 選擇性雌激素受體調節劑 (SERM)
  • 標靶治療
    • 曲妥珠單抗
    • 帕妥珠單抗
    • Everolimus
    • 阿多曲妥珠單抗emtansine
    • Palbociclib
    • 瑞博西尼
    • 奧拉帕尼
    • Abemaciclib
  • 化療
  • 免疫療法
  • 其他治療方法

第6章全球乳癌治療市場：依癌症類型分類

  • HER2+
  • 荷爾蒙受體

第7章全球乳癌治療市場：依通路分類

  • 零售藥房
  • 醫院藥房
  • 網路藥房

第8章全球乳癌治療市場：依最終用戶分類

  • 調查機構
  • 診斷中心
  • 診所
  • 其他最終用戶

第9章全球乳癌治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Exelixis Inc.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Novartis AG
  • Perkin Elmer Inc.
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • NanoString Technologies Inc.
  • Daiichi Sankyo Co. Ltd.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb
  • Clovis Oncology
Product Code: SMRC24804

According to Stratistics MRC, the Global Breast Cancer Therapeutics Market is accounted for $29.1 billion in 2023 and is expected to reach $54.3 billion by 2030 growing at a CAGR of 9.3% during the forecast period. Breast cancer therapeutics refers to the various treatments and interventions designed to manage, treat, or cure breast cancer. These therapeutics encompass a wide range of approaches, including surgery, chemotherapy, radiation therapy, targeted therapy, hormone therapy, immunotherapy, and newer emerging treatments like precision medicine and gene therapy. Therapeutic approaches often vary based on the stage of the cancer, its specific characteristics, and the individual patient's health and preferences.

According to the Breast Cancer Organizations statistics, as of January 2022, breast cancer affects more than 3.8 million American women. The statistics indicate that in the year 2022, around 30% of newly diagnosed cancers among women are estimated to be breast cancer cases.

Market Dynamics:

Driver:

Rising incidence of breast cancer

The increasing prevalence of breast cancer globally prompts greater demand for therapeutic options, spurring research and development efforts. Emerging technologies offer more targeted therapies, improving efficacy and reducing side effects. The growing awareness of early detection emphasizes the need for comprehensive treatment solutions, creating a conducive environment for market expansion. This surge in demand encourages competitive pricing strategies and fosters collaborations for enhanced patient care, propelling the market forward.

Restraint:

Adverse effects of therapeutics

Adverse reactions arising from breast cancer therapeutics, such as targeted therapies, may limit the market growth. In cases of severe adverse reactions, the patient may not be able to use that particular drug and may have to move toward other types of therapeutics. Side effects of treatments can be severe and impact the patient's quality of life.

Opportunity:

Expanding geriatric population

With an aging population worldwide, there's a higher incidence of cancer, including breast cancer, leading to a greater demand for therapeutic options. With advanced age being a primary risk factor for breast cancer, the growing demographic of older individuals creates a larger pool of potential patients. Additionally, increased awareness and improved screening methods within this population offer opportunities for early detection and intervention, fostering better treatment outcomes and market expansion.

Threat:

High cost of therapies

Many advanced breast cancer treatments are expensive, limiting access for patients without adequate insurance coverage or financial resources. Affordability issues lead to unequal access to innovative medications, impacting treatment efficacy and patient outcomes. High expenses also burden healthcare systems, constraining resources and potentially limiting research and development of newer, more accessible therapies. These cost barriers hinder the growth of the market.

Covid-19 Impact:

The coronavirus outbreak has disrupted the global economy, inflicting economic burden and financial adversities. Many sectors have witnessed drastic transition including the healthcare sector. Hospital admissions regarding COVID-19 affected patients were prioritized, with other medical procedures postponed. The pandemic has had a limited impact on this global market as this treatment is considered a life-saving treatment for several patients.

The targeted therapy segment is expected to be the largest during the forecast period

The targeted therapy segment is expected to be the largest during the forecast period. Targeted therapy in breast cancer offers precise treatment, attacking specific molecules crucial for cancer growth while sparing healthy cells. It enhances efficacy with reduced side effects compared to traditional treatments, improving patient outcomes. Their ability to prevent cancer's progression by pinpointing distinct pathways amplifies treatment effectiveness, promising better survival rates and a higher quality of life for patients.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period. Hospital pharmacies play a pivotal role in breast cancer therapeutics by ensuring timely access to specialized medications, optimizing drug regimens, and providing personalized care. They facilitate seamless coordination between healthcare teams, ensuring accurate dosing and monitoring of treatments, thereby enhancing patient outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to government initiatives, and the presence of key pharmaceutical companies. The region is dynamic, with ongoing research, clinical trials, and collaborations between pharmaceutical companies and research institutions driving innovation. It's also supported by strong healthcare infrastructure and favorable reimbursement policies, allowing patients access to advanced treatments.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors, including increasing awareness, advancements in technology and improved access to healthcare facilities. There's also a growing trend toward personalized medicine, where treatments are tailored based on the specific characteristics of the tumor. The adoption of advanced diagnostic tools and treatment modalities has significantly improved patient outcomes.

Key players in the market

Some of the key players in Breast Cancer Therapeutics market include Exelixis Inc., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Viatris Inc., Novartis AG, Perkin Elmer Inc., Pfizer Inc., Puma Biotechnology Inc., NanoString Technologies Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly and Co., AbbVie Inc., Amgen Inc., Bristol Myers Squibb and Clovis Oncology.

Key Developments:

In February 2023, Gilead Sciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Trodelvy to treat adult patients with inoperable locally advanced or metastatic breast cancer. This approval anticipates enhancing the available treatment choices and likely leading to improved outcomes for patients suffering from breast cancer.

In November 2022, Eli Lilly and Company launched the additional indication for Ramiven (abemaciclib), following approval from the Drugs Controller General of India (DCGI), in combination with endocrine therapy for adjuvant treatment in adult patients with Hormone Receptor (HR)-positive, HER2 negative, node-positive EBC at high risk of recurrence.

Therapies Covered:

  • Hormonal Therapy
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Other Therapies

Cancer Types Covered:

  • HER2+
  • Hormone Receptor

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

End Users Covered:

  • Research Institutions
  • Diagnostic Centers
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Breast Cancer Therapeutics Market, By Therapy

  • 5.1 Introduction
  • 5.2 Hormonal Therapy
    • 5.2.1 Aromatase Inhibitors
    • 5.2.2 Estrogen Receptor Downregulators (ERDs)
    • 5.2.3 Selective Estrogen Receptor Modulators (SERMs)
  • 5.3 Targeted Therapy
    • 5.3.1 Trastuzumab
    • 5.3.2 Pertuzumab
    • 5.3.3 Everolimus
    • 5.3.4 Ado-Trastuzumab Emtansine
    • 5.3.5 Palbociclib
    • 5.3.6 Ribociclib
    • 5.3.7 Olaparib
    • 5.3.8 Abemaciclib
  • 5.4 Chemotherapy
  • 5.5 Immunotherapy
  • 5.6 Other Therapies

6 Global Breast Cancer Therapeutics Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 HER2+
  • 6.3 Hormone Receptor

7 Global Breast Cancer Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacies
  • 7.3 Hospital Pharmacies
  • 7.4 Online Pharmacies

8 Global Breast Cancer Therapeutics Market, By End User

  • 8.1 Introduction
  • 8.2 Research Institutions
  • 8.3 Diagnostic Centers
  • 8.4 Clinics
  • 8.5 Other End Users

9 Global Breast Cancer Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Exelixis Inc.
  • 11.2 F. Hoffmann La Roche Ltd.
  • 11.3 GlaxoSmithKline Plc
  • 11.4 Merck and Co. Inc.
  • 11.5 Sanofi
  • 11.6 Teva Pharmaceutical Industries Ltd.
  • 11.7 Viatris Inc.
  • 11.8 Novartis AG
  • 11.9 Perkin Elmer Inc.
  • 11.10 Pfizer Inc.
  • 11.11 Puma Biotechnology Inc.
  • 11.12 NanoString Technologies Inc.
  • 11.13 Daiichi Sankyo Co. Ltd.
  • 11.14 Eisai Co. Ltd.
  • 11.15 Eli Lilly and Co.
  • 11.16 AbbVie Inc.
  • 11.17 Amgen Inc.
  • 11.18 Bristol Myers Squibb
  • 11.19 Clovis Oncology

List of Tables

  • Table 1 Global Breast Cancer Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Breast Cancer Therapeutics Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 3 Global Breast Cancer Therapeutics Market Outlook, By Hormonal Therapy (2021-2030) ($MN)
  • Table 4 Global Breast Cancer Therapeutics Market Outlook, By Aromatase Inhibitors (2021-2030) ($MN)
  • Table 5 Global Breast Cancer Therapeutics Market Outlook, By Estrogen Receptor Downregulators (ERDs) (2021-2030) ($MN)
  • Table 6 Global Breast Cancer Therapeutics Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2021-2030) ($MN)
  • Table 7 Global Breast Cancer Therapeutics Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 8 Global Breast Cancer Therapeutics Market Outlook, By Trastuzumab (2021-2030) ($MN)
  • Table 9 Global Breast Cancer Therapeutics Market Outlook, By Pertuzumab (2021-2030) ($MN)
  • Table 10 Global Breast Cancer Therapeutics Market Outlook, By Everolimus (2021-2030) ($MN)
  • Table 11 Global Breast Cancer Therapeutics Market Outlook, By Ado-Trastuzumab Emtansine (2021-2030) ($MN)
  • Table 12 Global Breast Cancer Therapeutics Market Outlook, By Palbociclib (2021-2030) ($MN)
  • Table 13 Global Breast Cancer Therapeutics Market Outlook, By Ribociclib (2021-2030) ($MN)
  • Table 14 Global Breast Cancer Therapeutics Market Outlook, By Olaparib (2021-2030) ($MN)
  • Table 15 Global Breast Cancer Therapeutics Market Outlook, By Abemaciclib (2021-2030) ($MN)
  • Table 16 Global Breast Cancer Therapeutics Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 17 Global Breast Cancer Therapeutics Market Outlook, By Immunotherapy (2021-2030) ($MN)
  • Table 18 Global Breast Cancer Therapeutics Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 19 Global Breast Cancer Therapeutics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 20 Global Breast Cancer Therapeutics Market Outlook, By HER2+ (2021-2030) ($MN)
  • Table 21 Global Breast Cancer Therapeutics Market Outlook, By Hormone Receptor (2021-2030) ($MN)
  • Table 22 Global Breast Cancer Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 23 Global Breast Cancer Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 24 Global Breast Cancer Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 25 Global Breast Cancer Therapeutics Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 26 Global Breast Cancer Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Breast Cancer Therapeutics Market Outlook, By Research Institutions (2021-2030) ($MN)
  • Table 28 Global Breast Cancer Therapeutics Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 29 Global Breast Cancer Therapeutics Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 30 Global Breast Cancer Therapeutics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.